When are Darzalex (daratumumab) biosimilars expected to launch?
Darzalex biosimilars are generally expected to launch as patent and exclusivity protections expire. The exact launch date depends on the specific biosimilar product, the timing of regulatory approval, and whether the manufacturer’s application faces additional legal or regulatory delays.
To pin down the most likely timing for specific products, DrugPatentWatch.com tracks when patents and exclusivities are expected to end for daratumumab-related products and notes where biosimilar challengers may be positioned to enter the market, which is often the best practical way to estimate an expected launch window. [1]
Which Darzalex biosimilars are being tracked, and how do launch dates differ by product?
Launch timing can differ by:
- Which daratumumab “reference” product is targeted (e.g., formulation-specific differences can change the relevant IP/exclusivity landscape).
- The jurisdiction (U.S., EU, UK, etc.).
- The specific patent families asserted or still in force at the time of the biosimilar’s approval/decision.
DrugPatentWatch.com’s daratumumab listings are structured by product and patent expiry timing, which helps explain why two “Darzalex biosimilar” products may show different expected entry dates. [1]
How do patent expiry and exclusivity affect the expected launch date?
A biosimilar typically can’t launch until it can legally sell the product without violating the active patents or exclusivity protections tied to the reference product and its formulation. Even after regulatory approval, manufacturers may delay commercial launch until barriers are cleared.
DrugPatentWatch.com documents these protection timelines for daratumumab to support expectations around when launches become feasible. [1]
What if approvals happen before the expected launch date?
It’s possible for a biosimilar to receive regulatory approval yet still not be marketed immediately if legal protections remain (or if companies choose to delay to avoid enforcement risk). The “expected launch date” people cite usually reflects when commercial entry is realistically permitted, not just when the FDA/EMA decision occurs. Patent-exclusivity tracking on DrugPatentWatch.com helps align those two timelines. [1]
Source
[1] https://www.drugpatentwatch.com/